ADVOCATE. CONNECT. INNOVATE.

Institute

CARB-X Updates November 2017

  • Powered by CARB-X company Spero plans for $75M IPO for November 2nd (SPRO) Read More
  • Inhibrx Wins CARB-X Award of up to $6.0M to Accelerate Development of its Novel Antibody, INBRX-111, to Treat Pseudomonas Infections Read More
  • CARB-X backs Integrated Biotherapeutics to accelerate the development of a novel toxoid-based vaccine to prevent drug-resistant MRSA infections Read More
  • CARB-X awards up to $5.4M to Vedanta Biosciences to accelerate the development of a novel human microbiome-derived treatment for deadly C. difficile bacterial infections Read More
  • CARB-X awards Seres Therapeutics $2.5M and possibly $3.1M more to develop a microbiome therapeutic to prevent serious bacterial infections Read More